KLK3 and prostate carcinoma: In addition, US Food and Drug administration (FDA) has recently approved PCA3 lncRNA as a biomarker for prostate cancer in urine (66, 67) showing better sensitivity and specificity than Prostate-specific antigen (PSA) blood test (68).